Leukocyte Recovery in Liver Transplant Recipients After Letermovir Conversion (WTC 2025) - Jul 30, 2025 - Abstract #P1.08.22; Pres time: Aug 3, 2025; 03:30 PM - 04:30 PM; Location: Exhibit Hall AB; "Patients were excluded if ganciclovir or valganciclovir was used for 7 days prior to LTV start. LTV may be an effective alternative CMV prophylaxis agent in liver transplant recipients, however further evaluation is needed to better assess hematologic recovery in this population."
Clinical • Cytomegalovirus Infection • Infectious Disease • Transplantation
|
|
S. Amin; A. Yun; M. Nigo; R. Ghobrial; A. Scott; A. Chaplain; A. Rogers
|